The Regulatory Fast Lane: How the FDA's Streamlined Pathways Are Unlocking In Vivo Gene Editing

The FDA just rewrote the rules for gene editing approvals. The companies that understand what changed — and which ones don't — will determine who wins the next decade of biotech.